US 12,466,849 B2
Anti-viral and anti-tumoral compounds
Helena Shomar Monges, Tel Aviv (IL); Rotem Sorek, Rehovot (IL); Lianet Noda Garcia, Tel Aviv (IL); Arthur Machlenkin, Gedera (IL); and David Sperandio, Palo Alto, CA (US)
Assigned to YEDA RESEARCH AND DEVELOPMENT CO. LTD., Rehovot (IL)
Filed by YEDA RESEARCH AND DEVELOPMENT CO. LTD, Rehovot (IL)
Filed on Jan. 25, 2022, as Appl. No. 17/583,378.
Application 17/583,378 is a continuation in part of application No. PCT/IB2021/057599, filed on Aug. 18, 2021.
Claims priority of provisional application 63/085,218, filed on Sep. 30, 2020.
Prior Publication US 2023/0072222 A1, Mar. 9, 2023
Int. Cl. C07H 19/20 (2006.01); A61P 31/14 (2006.01); C07H 19/10 (2006.01)
CPC C07H 19/20 (2013.01) [A61P 31/14 (2018.01); C07H 19/10 (2013.01)] 20 Claims
 
1. A compound represented by the structure of
Formula IIB:

OG Complex Work Unit Chemistry
or Formula IVB:

OG Complex Work Unit Chemistry
wherein
R1 is

OG Complex Work Unit Chemistry
Q is a side chain of an amino acid;
M1 is an alkyl;
M2 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl;
M4 is —(C2-C6)alkyl-O—(C10-C20)alkyl;
each M5 is —(CH2)n—S—C(═O)—(C1-C8)alkyl;
n is 1-4; and
R2 is —OH.